What are the indications, dosing regimens, contraindications, and precautions for Omnicef (cefdinir) in adults and children?

Omnicef (Cefdinir): Indications, Dosing, Contraindications, and Precautions

Omnicef (cefdinir) is an oral third-generation cephalosporin indicated for community-acquired respiratory tract infections, acute bacterial sinusitis, pharyngitis/tonsillitis, acute otitis media, and uncomplicated skin/skin structure infections in adults and children ≥6 months old. 1

FDA-Approved Indications

Adults and Adolescents (≥13 years)

• Community-acquired pneumonia
• Acute bacterial exacerbation of chronic bronchitis
• Acute maxillary sinusitis
• Pharyngitis/tonsillitis
• Uncomplicated skin and skin structure infections

Pediatric Patients (6 months-12 years)

• Acute bacterial otitis media
• Acute maxillary sinusitis
• Pharyngitis/tonsillitis
• Uncomplicated skin and skin structure infections

Dosing Regimens

Adults and Adolescents (≥13 years)

• Standard dose: 300 mg twice daily OR 600 mg once daily
• Duration: 5-10 days depending on infection type 1

Pediatric Patients (6 months-12 years)

The total daily dose is 14 mg/kg (maximum 600 mg/day), administered as:

• 7 mg/kg every 12 hours OR
• 14 mg/kg once daily 1

Important exception: For uncomplicated skin infections in children, use only twice-daily dosing (7 mg/kg every 12 hours), as once-daily dosing has not been studied for this indication 1

Specific Infection Durations

• Acute bacterial otitis media: 5-10 days
• Acute maxillary sinusitis: 10 days
• Pharyngitis/tonsillitis: 5-10 days
• Uncomplicated skin infections: 10 days 1

Renal Dosing Adjustments

For creatinine clearance <30 mL/min:

• Adults: 300 mg once daily
• Pediatric: 7 mg/kg once daily (maximum 300 mg) 1

Hemodialysis patients:

• Initial dose: 300 mg (or 7 mg/kg) every other day
• After each dialysis session: give 300 mg (or 7 mg/kg)
• Subsequent doses: every other day 1

Guideline-Based Recommendations

Acute Bacterial Sinusitis

Cefdinir is recommended as an alternative agent for patients with penicillin hypersensitivity (both type 1 and non-type 1 reactions) when treating acute bacterial sinusitis 2. First-line therapy remains amoxicillin or amoxicillin-clavulanate, but cefdinir provides appropriate coverage when beta-lactam allergy precludes penicillin use.

Community-Acquired Pneumonia in Children

For pediatric pneumonia caused by β-lactamase-producing Haemophilus influenzae, cefdinir is listed as an alternative oral agent alongside cefixime, cefpodoxime, and ceftibuten 3. However, it is not a preferred first-line agent for typical bacterial pneumonia.

Skin and Soft Tissue Infections

While cefdinir has demonstrated efficacy in uncomplicated skin infections 4, 5, it is not specifically recommended in IDSA guidelines for skin and soft tissue infections, which favor agents with more robust anti-staphylococcal activity 6, 7.

Contraindications and Precautions

Absolute Contraindications

• Known hypersensitivity to cefdinir or other cephalosporins 1

Important Precautions

Penicillin Cross-Reactivity: Approximately 10% of penicillin-allergic patients may have cross-reactivity with cephalosporins. Use with caution in patients with documented penicillin allergy, particularly type 1 hypersensitivity reactions 1.

Renal Impairment: Dose adjustment is mandatory when creatinine clearance falls below 30 mL/min, as cefdinir is primarily renally eliminated 1.

Gastrointestinal Effects: Diarrhea is the most common adverse event, occurring more frequently than with comparator agents in multiple trials 5, 8. This may limit tolerability in some patients.

Drug Interactions:

• Iron supplements and antacids containing aluminum or magnesium: Reduce cefdinir absorption; separate administration by at least 2 hours 1
• Probenecid: May increase cefdinir plasma concentrations 1

Pregnancy and Lactation: Cefdinir is FDA Pregnancy Category B. While generally considered safe, use only when clearly needed 1.

Critical Clinical Considerations

When NOT to Use Cefdinir

Urinary tract infections: Recent evidence demonstrates that cefdinir is associated with significantly higher treatment failure rates (23.4% vs 12.5%) compared to cephalexin for uncomplicated UTIs 9. Patients failing cefdinir therapy showed higher rates of cephalosporin-resistant pathogens on repeat culture 9. Cephalexin is strongly preferred over cefdinir for UTI treatment 10.

Serious infections requiring parenteral therapy: Cefdinir's oral bioavailability is only 16-25% 1, making it inappropriate for severe infections, bacteremia, or hospitalized patients requiring intravenous therapy.

Meningitis: Cefdinir does not achieve adequate CSF concentrations and should never be used for CNS infections 1.

Antimicrobial Spectrum

Good activity against:

• Streptococcus pneumoniae (penicillin-susceptible strains)
• Streptococcus pyogenes
• Haemophilus influenzae (including β-lactamase producers)
• Moraxella catarrhalis (including β-lactamase producers)
• Methicillin-susceptible Staphylococcus aureus 4, 5

Poor or no activity against:

• Methicillin-resistant Staphylococcus aureus (MRSA)
• Pseudomonas aeruginosa
• Atypical pathogens (Mycoplasma, Chlamydia)
• Anaerobes 4, 5

Administration Considerations

Food effects: While high-fat meals reduce absorption by 16-44% 1, cefdinir may be administered without regard to meals, as pediatric efficacy studies did not control for food intake 1.

Suspension stability: After reconstitution, suspension remains stable for 10 days at room temperature (20-25°C); discard unused portion after this period 1.

Taste acceptability: Cefdinir suspension demonstrates superior palatability compared to other oral antimicrobials, which may improve adherence in pediatric patients 5.

Resistance Considerations

Avoid for empiric therapy when:

• Local resistance rates to trimethoprim-sulfamethoxazole and macrolides are high, as cross-resistance patterns may affect cephalosporin efficacy 2
• Penicillin-resistant S. pneumoniae is suspected (MIC >0.5 mcg/mL), as cefdinir may have reduced activity 11

Rare but Serious Adverse Events

One case report documents cefdinir-associated myopericarditis presenting with pleuritic chest pain, elevated troponins, and pericardial effusion 12. While extremely rare, this highlights the importance of considering drug-induced causes in patients developing cardiac symptoms during cefdinir therapy.